SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $6.00

SAB Biotherapeutics (NASDAQ:SABSGet Free Report) had its target price dropped by equities research analysts at HC Wainwright from $10.00 to $6.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 34.53% from the company’s current price.

SAB Biotherapeutics Trading Down 0.9 %

NASDAQ:SABS opened at $4.46 on Tuesday. SAB Biotherapeutics has a 12-month low of $3.66 and a 12-month high of $14.50. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.34 and a quick ratio of 0.34. The firm has a 50-day moving average price of $5.21 and a 200 day moving average price of $2.85.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of SAB Biotherapeutics by 5.6% during the first quarter. Vanguard Group Inc. now owns 721,151 shares of the company’s stock worth $2,712,000 after buying an additional 38,179 shares in the last quarter. State Street Corp increased its holdings in shares of SAB Biotherapeutics by 244.2% during the first quarter. State Street Corp now owns 42,341 shares of the company’s stock worth $159,000 after buying an additional 30,041 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of SAB Biotherapeutics during the second quarter worth approximately $93,000. Citadel Advisors LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth approximately $28,000. Finally, HighTower Advisors LLC acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter worth approximately $44,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

Read More

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.